Glaxosmithkline Plc
- All
- News
-
2 New Medicines For Covid Treatment Get WHO Approval
Eli Lilly & Co.'s rheumatoid arthritis drug and GlaxoSmithKline Plc's monoclonal antibody won the backing of World Health Organization experts for treating Covid-19 as new infections surge across the globe.
-
All 37 Omicron Mutations Defeated By This New Antibody Treatment
GlaxoSmithKline Plc said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new omicron variant.
-
Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
-
French Drugmaker Sanofi Expects Approval Of COVID-19 Vaccine By Next Year
French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.
-
Government's Plan To Pull In 324 Companies Including Tesla, Glaxo: Report
The government is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in India in a bid to capitalize from the trade war between China and the US., according to a document seen by Bloomberg.
-
GlaxoSmithKline In Exclusive Talks To Sell Horlicks Unit To Unilever: Report
Unilever beat a bid from Swiss rival Nestle which was also bidding for the unit and looking to expand its portfolio in the powdered hot beverages category, the report added.
-
Glaxo Seeks Mid-September Bids For $4 Billion Indian Horlicks Unit: Report
UK pharmaceutical giant GlaxoSmithKline Plc has requested bids by mid-September for its $4.3 billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
UK Competition Authorities Fine GlaxoSmithKline $54.5 Million
Britain's competition authority has fined drug maker GlaxoSmithKline plc 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.
-
You Probably Have Herpes: WHO
Two-thirds of the world's population under 50 have the highly infectious herpes virus that causes cold sores around the mouth, the World Health Organization said on Wednesday, in its first estimate of global prevalence of the disease.
-
Cipla Expects to Double Respiratory Drug Sales by 2020
Cipla Ltd, India's fourth-largest drug maker by revenue, expects sales from its respiratory drug portfolio to more than double by 2020 and remains on track to launch a keenly awaited inhaler in Britain, its chief executive said.
-
Novartis Okays OTC Unit Sale to GSK Consumer
The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.
-
Novartis-GSK Pharma Deal Cleared by CCI
The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.
-
China Hands GlaxoSmithKline Record $489 Million Fine
China fined GlaxoSmithKline Plc a record 3 billion yuan ($490 million) on Friday for paying bribes to doctors to use its drugs, underlining the risks of doing business there while also ending a damaging chapter for the British drug maker.
-
US Emergency Labs Ready to Work on Ebola Drugs if Asked
All three US facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.
-
2 New Medicines For Covid Treatment Get WHO Approval
Eli Lilly & Co.'s rheumatoid arthritis drug and GlaxoSmithKline Plc's monoclonal antibody won the backing of World Health Organization experts for treating Covid-19 as new infections surge across the globe.
-
All 37 Omicron Mutations Defeated By This New Antibody Treatment
GlaxoSmithKline Plc said research shows its Covid-19 antibody treatment is effective against the full combination of mutations in the new omicron variant.
-
Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
-
French Drugmaker Sanofi Expects Approval Of COVID-19 Vaccine By Next Year
French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.
-
Government's Plan To Pull In 324 Companies Including Tesla, Glaxo: Report
The government is planning to offer 324 companies including Tesla Inc. and GlaxoSmithKline Plc incentives to set up factories in India in a bid to capitalize from the trade war between China and the US., according to a document seen by Bloomberg.
-
GlaxoSmithKline In Exclusive Talks To Sell Horlicks Unit To Unilever: Report
Unilever beat a bid from Swiss rival Nestle which was also bidding for the unit and looking to expand its portfolio in the powdered hot beverages category, the report added.
-
Glaxo Seeks Mid-September Bids For $4 Billion Indian Horlicks Unit: Report
UK pharmaceutical giant GlaxoSmithKline Plc has requested bids by mid-September for its $4.3 billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said.
-
In Fight For GSK's Advair, Generic Firms Step Carefully On Price
Generic drugmakers, hoping for rich pickings from the launch of copies of GlaxoSmithKline's best-selling Advair inhaler in the United States next year, say they can win business without a race to the bottom on price.
-
UK Competition Authorities Fine GlaxoSmithKline $54.5 Million
Britain's competition authority has fined drug maker GlaxoSmithKline plc 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of an anti-depressant drug Seroxat into the marketplace.
-
You Probably Have Herpes: WHO
Two-thirds of the world's population under 50 have the highly infectious herpes virus that causes cold sores around the mouth, the World Health Organization said on Wednesday, in its first estimate of global prevalence of the disease.
-
Cipla Expects to Double Respiratory Drug Sales by 2020
Cipla Ltd, India's fourth-largest drug maker by revenue, expects sales from its respiratory drug portfolio to more than double by 2020 and remains on track to launch a keenly awaited inhaler in Britain, its chief executive said.
-
Novartis Okays OTC Unit Sale to GSK Consumer
The move follows a global deal struck in April last year, under which Swiss-based Novartis AG had agreed with UK-based GlaxoSmithKline plc to create a global consumer healthcare joint venture, GlaxoSmithKline Consumer Private Ltd (GSK CPL), as part of its global portfolio transformation.
-
Novartis-GSK Pharma Deal Cleared by CCI
The Competition Commission of India (CCI) has approved a multi-billion dollar deal between global pharma giants GlaxoSmithKline Plc and Novartis, as it does not find the transaction to be anti-competitive in India.
-
China Hands GlaxoSmithKline Record $489 Million Fine
China fined GlaxoSmithKline Plc a record 3 billion yuan ($490 million) on Friday for paying bribes to doctors to use its drugs, underlining the risks of doing business there while also ending a damaging chapter for the British drug maker.
-
US Emergency Labs Ready to Work on Ebola Drugs if Asked
All three US facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.
